New York, January 09, 2014 -- Moody's Investors Service assigned a Ba3 rating to the new senior secured revolver of Jazz Financing I, Ltd., a wholly owned subsidiary of Jazz Pharmaceuticals plc. ("collectively referred to as Jazz"). Concurrently, Moody's affirmed the Ba3 Corporate Family Rating and bank credit facilities as well as the B1-PD Probability of Default Rating and SGL-1 Speculative Grade Liquidity Rating. Moody's affirmed the term loan of Jazz Pharmaceuticals, Inc. which is being upsized by up to $400 million.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.